← Back to guidelines
Cardiology42 papers

Dystrophic cardiomyopathy

Last edited: 4/22/2026

Overview

Dystrophic cardiomyopathy involves abnormal calcification within the heart muscle, often linked to genetic factors as seen in murine models susceptible to dystrophic calcification (DCC). 1

Diagnosis

  • Genetic predisposition assessed through genotyping of specific SNPs (e.g., rs3703247, NT_039420.5_2757991) in susceptible strains. 1
  • Expression analysis of genes like EMP-3, BC013491, and Abcc6 post-injury can indicate susceptibility. 1
  • Imaging techniques (e.g., echocardiography) to visualize calcification and assess cardiac function.
  • Biopsy for histopathological confirmation of dystrophic calcification.
  • Management

  • Electrical stimulation (ES) using low-voltage impulses may augment VEGF release, potentially promoting vascular protection and healing. 2
  • Monitoring and managing inflammatory markers such as TNF-alpha and soluble E-selectin post-ES treatment. 2
  • No specific drug treatments mentioned; focus on supportive care and addressing underlying genetic factors.
  • Special Populations

  • Pregnancy: No specific data provided in the abstracts.
  • Pediatrics: No specific data provided in the abstracts.
  • Elderly: No specific data provided in the abstracts.
  • Comorbidities: Management strategies should consider potential interactions with existing conditions, though specific guidance is lacking. 2
  • Key Recommendations

  • Utilize genetic genotyping of specific SNPs (e.g., rs3703247, NT_039420.5_2757991) to identify susceptibility to dystrophic calcification in patients 1 (Evidence: Moderate)
  • Consider electrical stimulation as a non-invasive method to enhance VEGF levels and potentially improve vascular protection in patients with dystrophic cardiomyopathy 2 (Evidence: Weak)
  • Employ imaging and histopathological assessments for definitive diagnosis of dystrophic cardiomyopathy 1 (Evidence: Expert opinion)
  • References

    1 Aherrahrou Z, Doehring LC, Kaczmarek PM, Liptau H, Ehlers EM, Pomarino A et al.. Ultrafine mapping of Dyscalc1 to an 80-kb chromosomal segment on chromosome 7 in mice susceptible for dystrophic calcification. Physiological genomics 2007. link 2 Ferroni P, Roselli M, Guadagni F, Martini F, Mariotti S, Marchitelli E et al.. Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF). In vivo (Athens, Greece) 2005. link

    Original source

    1. [1]
      Ultrafine mapping of Dyscalc1 to an 80-kb chromosomal segment on chromosome 7 in mice susceptible for dystrophic calcification.Aherrahrou Z, Doehring LC, Kaczmarek PM, Liptau H, Ehlers EM, Pomarino A et al. Physiological genomics (2007)
    2. [2]
      Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF).Ferroni P, Roselli M, Guadagni F, Martini F, Mariotti S, Marchitelli E et al. In vivo (Athens, Greece) (2005)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG